A once-daily, highly selective VMAT2 inhibitor. Compared with tetrabenazine, valbenazine and deutetrabenazine have demonstrated more favorable safety profiles and simpler dosing. FDA-approved for HD-associated chorea in 2023.
Dosing Notes
Once-daily oral capsule; typical starting dose 40 mg, titrated to 80 mg based on response.
Treatment Type
pharmaceutical
Clinical Evidence
What the Evidence Shows
Each finding below is linked to its primary source. Confidence levels reflect the quality and quantity of available evidence — not CelluTarget's endorsement of any treatment.
High: Supported by multiple robust studies or regulatory approval
Moderate: Supported by limited controlled studies or consistent case series
Low: Based on case reports, expert opinion, or early-phase data only
High ConfidenceSupported by multiple robust studies or regulatory approval
Valbenazine received FDA approval in 2023 for HD-associated chorea (KINECT-HD trial, NCT04102579), with a once-daily dosing schedule and a tolerability profile comparable to deutetrabenazine.
Verified Jul 2026
Peer Reviewed
Treatment Considerations With VMAT2 Inhibitors for Chorea in Huntington Disease